BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 2,695 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $25.44, for a total value of $68,560.80. Following the transaction, the insider now owns 43,165 shares in the company, valued at approximately $1,098,117.60. This represents a 5.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The shares were sold at an average price of $24.96, for a total value of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Trading Down 2.3 %

Shares of NASDAQ:BLFS opened at $25.33 on Wednesday. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The company has a market capitalization of $1.19 billion, a PE ratio of -23.90 and a beta of 2.04. The business has a 50 day moving average of $26.53 and a two-hundred day moving average of $25.49. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the previous year, the company posted ($0.21) earnings per share. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp upped their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, HC Wainwright upped their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions during the 4th quarter worth approximately $31,000. Quest Partners LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $57,000. Finally, 1620 Investment Advisors Inc. raised its stake in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.